A new US patent allowance broadens protection around RenovoRx’s dual-occlusion drug-delivery catheter as commercial revenue grows and the separate TIGeR-PaC drug-device programme moves toward 2027 data.
Senhwa Biosciences has secured Taiwan regulatory clearance for a multicenter Phase 1b/2a trial combining pidnarulex, or CX-5461, with BeOne Medicines’ PD-1 inhibitor tislelizumab in advanced solid tumors. The study will test whether DNA replication stress can make immunologically cold or checkpoint-resistant cancers more responsive to immunotherapy.
Eli Lilly and Company has secured an expedited United States regulatory pathway for olomorasib in a rare, previously treated pancreatic cancer population. The designation increases FDA engagement around the programme, but the investigational therapy still needs a pancreatic cancer-specific evidence package capable of supporting approval.
KRAS G12D was long seen as nearly untouchable. Ranok’s RNK08954 now has early clinical data, but the pivotal test is still ahead.
See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.
RenovoRx’s ASCO 2026 data highlights how targeted gemcitabine delivery could reshape pancreatic cancer treatment strategy. Read more.
ClearNote Health will present Avantect pancreatic cancer test validation data at ASCO 2026. Find out what it could mean for early detection.
Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.
Actuate Therapeutics, Inc. is advancing oral elraglusib after FDA IND clearance. Discover what this means for pancreatic cancer economics.
Pancreatic cancer needs local precision. Vector Science is betting a catheter patent can move drug delivery closer to the tumor.